Early administration of hydrocortisone replacement after the advent of septic shock: Impact on survival and immune response

Critical Care Medicine

Volumn 42, Issue 7, 2014, Pages 1651-1657

  Katsenos, Chrysostomos S ^a   Antonopoulou, Anastasia N ^b   Apostolidou, Efterpi N ^c   Ioakeimidou, Aikaterini ^d   Kalpakou, Georgia Th ^e   Papanikolaou, Metaxia N ^f   Pistiki, Aikaterini C ^b   Mpalla, Margarita C ^f   Paraschos, Michael D ^a   Patrani, Maria A ^a   Pratikaki, Maria E ^b   Retsas, Theodoros A ^b   Savva, Athina A ^b   Vassiliagkou, Spyridoula D ^g   Lekkou, Alexandra A ^h   Dimopoulou, Ioanna ^b   Routsi, Christina ^b   Mandragos, Konstantinos E ^a  

^a Intensive Care Unit   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Ptolemaida General Hospital   (Greece)

^d Korinthos General Hospital   (Greece)

^e Zakynthos General Hospital   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

^g G GENNIMATAS GENERAL HOSPITAL   (Greece)

^h UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

critical illness; critical illness related corticosteroid insufficiency; hydrocortisone; outcome; relative adrenal insufficiency; sepsis; septic shock; steroid replacement; tumor necrosis factor

Indexed keywords

HYDROCORTISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APACHE; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE UNIT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL; THERAPY DELAY; TIME TO TREATMENT;

AGED; AGED, 80 AND OVER; COMORBIDITY; CYTOKINES; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INTENSIVE CARE UNITS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TIME FACTORS; VASOCONSTRICTOR AGENTS;

EID: 84902535677     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000318     Document Type: Article

References (18)

1. Prigent H, Maxime V, Annane D: Science review: Mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 2004; 8:243-252
2. Marik PE: Critical illness-related corticosteroid insufficiency. Chest 2009; 135:181-193
3. Boonen E, Vervenne H, Meersseman P, et al: Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368:1477-1488
4. Gomez-Sanchez CE: Adrenal dysfunction in critically ill patients. N Engl J Med 2013; 368:1547-1549
5. Ledderose C, Möhnle P, Limbeck E, et al: Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-α. Crit Care Med 2012; 40:2745-2753
6. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
7. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
8. Moreno R, Sprung CL, Annane D, et al: Time course of organ failure in patients with septic shock treated with hydrocortisone: Results of the Corticus study. Intensive Care Med 2011; 37:1765-1772
9. Beale R, Janes JM, Brunkhorst FM, et al: Global utilization of low-dose corticosteroids in severe sepsis and septic shock: A report from the PROGRESS registry. Crit Care 2010; 14:R102
10. Huh JW, Choi HS, Lim CM, et al: Low-dose hydrocortisone treatment for patients with septic shock: A pilot study comparing 3 days with 7 days. Respirology 2011; 16:1088-1095
11. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
12. Marik PE, Pastores SM, Annane D, et al; American College of Critical Care Medicine: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-1949
13. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
14. Park HY, Suh GY, Song JU, et al: Early initiation of low-dose corticosteroid therapy in the management of septic shock: A retrospective observational study. Crit Care 2012; 16:R3
15. Annane D, Bellissant E, Sebille V, et al: Impaired pressor sensitivity to norepinephrine in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46: 589-597
16. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, et al: Ex-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: Correlation with disease severity. Cytokine 2010; 49:89-94
17. Keh D, Boehnke T, Weber-Cartens S, et al: Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512-520
18. Oppert M, Schindler R, Husung C, et al: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33:2457-2464